CD274 and non-small cell lung carcinoma: While FDA-approved for adjuvant chemotherapy in patients with stage II–III NSCLC with PD-L1 ≥ 1%, the European Medicines Agency requires high PD-L1 levels (≥50%) for patients to qualify.